论文部分内容阅读
患者女，66岁，因头皮、颈部水疱1个月就诊。既往有2型糖尿病病史6年，于起疹前6个月开始口服二肽基肽酶4抑制剂利格列汀5 mg每日1次。皮肤科检查：头皮散在绿豆至花生米大小水疱，部分水疱破溃，可见渗出、结痂；左侧颈部一鸽蛋大小大疱及2个绿豆大小水疱，疱壁紧张，疱液清亮，基底无明显红斑，尼氏征阴性。酶联免疫吸附试验示抗BP180 NC16A抗体5.81 kU/L、抗BP230抗体139.76 kU/L。颈部皮损组织病理检查示表皮下水疱形成，疱内中性粒细胞及少许嗜酸性粒细胞浸润。诊断：BP230型局限型大疱性类天疱疮。该例二肽基肽酶4抑制剂相关的BP230型大疱性类天疱疮为国内首次报道。“,”A 66-year-old female patient presented with blisters on the scalp and neck for 1 month. She had a history of type 2 diabetes for 6 years, and started taking the dipeptidyl peptidase-4 inhibitor linagliptin at a dose of 5 mg once a day 6 months before the onset of eruption. Skin examination showed scattered mung bean- to peanut-sized blisters on the scalp, and some blisters broke with exudation and crusts. There was a pigeon egg-sized bulla and two mung bean-sized blisters on the left neck, with tense blister walls, clear blister fluids, non-erythematous base, and Nikolsky′s sign was negative. Enzyme-linked immunosorbent assay revealed that the serum levels of anti-BP180 NC16A and anti-BP230 antibodies were 5.81 and 139.76 kU/L respectively. Histopathological examination of the blister on the neck showed subepidermal blister formation, and infiltration with neutrophils and a few eosinophils in the blister. The patient was finally diagnosed with localized anti-BP230-type bullous pemphigoid. This case of anti-BP230-type bullous pemphigoid associated with the dipeptidyl peptidase-4 inhibitor linagliptin was firstly reported in China.